Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Dexcom

Dow Jones Futures: Apple Holds, Amazon Joins Megacap Meltdown; What To Do Now

Apple dipped after the iPhone giant topped views. Amazon crashed on guidance, joining the megacap earnings meltdown.

Investors Business Daily

This Is What Whales Are Betting On DexCom

Someone with a lot of money to spend has taken a bullish stance on DexCom (NASDAQ:DXCM). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Diabetes patients can now get ‘life-changing’ blood sugar gadget on the NHS

Cutting edge technology could be beginning of the end for people needing to draw blood several times a day to test their levels

Daily Mirror

From analysis to the latest developments in health,
read the most diverse news in one place.

Benzinga's Top Ratings Upgrades, Downgrades For July 15, 2022

Benzinga

The UK’s First Diabetic Giant Anteater Has Been Fitted With A Glucose Monitor

The first diabetic giant anteater in the United Kingdom has been fitted with a monitor to check its blood glucose levels – which is normally used on humans.

Zenger

Here's How Much You Would Have Made Owning DexCom Stock In The Last 15 Years

DexCom (NASDAQ:DXCM) has outperformed the market over the past 15 years by 20.9% on an annualized basis producing an average annual return of 27.35%. Currently, DexCom has a market capitalization of $30.77 billion.

Benzinga

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $16,000 Today

DexCom (NASDAQ:DXCM) has outperformed the market over the past 5 years by 64.52% on an annualized basis producing an average annual return of 74.42%. Currently, DexCom has a market capitalization of $115.32 billion.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Elon Musk And Tesla Finally Get Good News In June

June is a month some S&P 500 investors would like to skip. But it's still a good month to stay engaged with stocks, especially Elon Musk's Tesla.

Investors Business Daily

Here's How Much You Would Have Made Owning DexCom Stock In The Last 15 Years

DexCom (NASDAQ:DXCM) has outperformed the market over the past 15 years by 22.06% on an annualized basis producing an average annual return of 28.95%. Currently, DexCom has a market capitalization of $29.24 billion.

Benzinga

Dexcom Pops After Insulet Buyout Rumor Shakes Up Diabetes Stocks

Dexcom stock popped Tuesday after the diabetes devices company refuted rumors that it's in active negotiations to acquire any company.

Investors Business Daily

What Are Whales Doing With DexCom

A whale with a lot of money to spend has taken a noticeably bearish stance on DexCom. Looking at options history for DexCom (NASDAQ:DXCM) we detected 25 strange trades.

Benzinga

How The Rumored Dexcom-Insulet Marriage Could Rock The Entire Diabetes Space

Dexcom stock yo-yoed Wednesday after a Tuesday dive on rumors it's in talks to acquire insulin pump-maker Insulet in a major diabetes deal.

Investors Business Daily

Dexcom In Talks To Acquire Insulet, Create a Giant In Diabetes Devices: Bloomberg

Dexcom Inc (NYSE:DXCM) is reportedly in talks to acquire medical-device company Insulet Corporation (NASDAQ: PODD) to create a giant in diabetes devices, according to people with knowledge of the matter. According to Bloomberg, talks between the companies are ongoing, and an agreement could be reached in the coming weeks. Discussions could still be delayed or fall…

Benzinga

DexCom Earnings Perspective: Return On Invested Capital

Pulled from Benzinga Pro data, DexCom (NASDAQ:DXCM) posted Q1 earnings of $97.30 million, an increase from Q4 of 601.55%. Sales dropped to $628.80 million, a 9.94% decrease between quarters.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

If You Invested $1000 In DexCom 10 Years Ago, Here's How Much You Would Have Today

DexCom (NASDAQ:DXCM) has outperformed the market over the past 10 years by 32.66% on an annualized basis producing an average annual return of 44.4%. Currently, DexCom has a market capitalization of $39.95 billion.

Benzinga

Read Here Why Did This Analyst Cut DexCom's Price Target

Benzinga

Recap: DexCom Q1 Earnings

DexCom (NASDAQ:DXCM) reported its Q1 earnings results on Thursday, April 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings DexCom missed estimated earnings by 38.46%, reporting an EPS of $0.32 versus an estimate of $0.52.

Investors Business Daily

Diabetes Giant Dexcom Snagged On Unexpectedly Low Profit, Sales Outlook

Dexcom stock dipped late Thursday after the diabetes devices company reported lighter-than-expected first-quarter profit.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

DexCom's Earnings: A Preview

DexCom (NASDAQ:DXCM) is set to give its latest quarterly earnings report on Thursday, 2022-04-28. Here's what investors need to know before the announcement. Analysts estimate that DexCom will report an earnings per share (EPS) of $0.52.

Benzinga

Here's How Much $100 Invested In DexCom 5 Years Ago Would Be Worth Today

DexCom (NASDAQ:DXCM) has outperformed the market over the past 5 years by 32.15% on an annualized basis producing an average annual return of 45.92%. Currently, DexCom has a market capitalization of $49.71 billion.

Investors Business Daily

Dexcom Stock Shows Market Leadership With Jump To 86 RS Rating

Dexcom shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 86.

Investors Business Daily

Dexcom Snags A New Diabetes Device Win After Covid-Related Delay

European officials approved Dexcom's newest body-worn diabetes device on Monday, leading Dexcom stock to surge closer to its 50-day line.

Benzinga

Dexcom G7 Continuous Glucose Monitoring System Receives European CE Mark

DexCom Inc's (NASDAQ: DXCM) Dexcom G7 Continuous Glucose Monitoring (CGM) System has

Benzinga

DexCom's Glucose Monitoring System Snags Breakthrough Device Tag For Hospital Use

The

StockNews.com

2 Upgraded Diabetes Stocks to Add to Your Watchlist

Diabetes has become one of the leading causes of death for Americans, claiming more than 100,000 lives in 2021. But the disease’s prevalence represents promising prospects for the diabetes care devices market. Given this backdrop, analysts have recently upgraded diabetes stocks DexCom (DXCM) and Insulet (PODD). Thus, these stocks could…

1 … 6 7 8 9

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

SP Global Market Intelligence

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.